



COVID-19 UPDATE

PHARMACY PROCESS

REMDESIVIR UTILISATION

Version 2: What is new?

- **Additional remdesivir supplier**
- **Order directly from IHS**
- **NO BULK ORDERS – Order per patient**

Current evidence

The recent publication of the World Health Organization (WHO) Solidarity Trial concluded that remdesivir had **no or little effect on the 28-day mortality and did not delay the need for ventilation or duration of hospital stay.**¹

The treatment is **not supported** by the South African National Essential Medicines List Committee (NEMLC) and is only available on a Section 21 Institutional Emergency Use Authorisation from the South African Health Products Regulatory Authority (SAHPRA).

Current Cipremi® stock from Cipla

Cipremi® stock levels is reduced to a minimum in all Mediclinic hospitals and there is currently no additional Cipremi® available. Once the stock is available we will inform the pharmacies.

Remdesivir from an alternative supplier:

Additional remdesivir (Remdinil™) manufactured by Square Pharmaceuticals in Bangladesh will be available from Forrester Pharma (PTY) LTD via HIS.

TO OPEN THE CODE

The code will be opened for the hospital after the following documentation is submitted to andriette.vanjaarsveld@mediclinic.co.za:

- **New Section 21 Approval from SAHPRA for Remdinil™**
Submit application on

https://docs.google.com/forms/d/e/1FAIpQLSdEsZ-DTXsG9xEF7aykM8n9WtzR1E42krGoQ_nz18szCSFmQ/viewform

- Apply for anticipated stock for 6 months – **but don't order the full quantity**
- **Submission** of a comprehensive and **updated Experimental treatment Excel tool**

ORDERING

Order direct via IHS via email

- Once the hospital receives the Section 21 authorisation and the code is opened, it must be sent to IHS, together with your Purchase order (with account details) and email:
- orders.ihs@imperiallogistics.com; Wendy.Fipaza@imperiallogistics.com; Glory.Mkabe@imperiallogistics.com
- CC: fatima.booyesen@forresterpharma.com and danie@forresterpharma.com in all emails
- Add **Emergency** in the subject line
- Include SAHPRA Section 21 approval letter
- Remdinil (section 21) concentrate for solution vial 100 mg per 20 mL INF
- Nappi code: 3002138001
- AS400 Code: REMD001
- **NO BULK ORDERS**. Order the absolute minimum number of treatment courses. The hospital is to take responsibility for *all* obsolete stock.
- We strongly recommend that you order single courses or as little possible at a time and rather place more regular orders.
- **You still need to complete the Experimental treatment forms**

DISPENSING OF REMDESIVIR

Remdesivir may only be dispensed if the following is adhered to:

- **Signed Patient Informed Consent**
 - Acknowledge liability of the account if medical aid refuse funding. Remdesivir is not PMB level of care
 - Acknowledge limited evidence of effectiveness
- **Medical Aid Approval**
- **Completion of the mandatory SAHPRA and MCSA reports – these reports will allow the hospital to replenish stock.**

Refer to COVID-19: CORPORATE GUIDELINE REMDESIVIR USE VS1 for the indication, dosage, administration and side-effects.

REPORTING REQUIREMENTS

1. SAHPRA Mandatory Report form:

<https://docs.google.com/forms/d/e/1FAIpQLSe1OwsYZeohug3Lnb6j61a1IYRbS0xEhdzVmosAlw5Zomh82w/viewform>

2. Mediclinic Experimental Treatment Form

An updated Mediclinic Experimental Treatment Excel tool must be submitted for ALL the patients that received remdesivir at the end of January 2021.

References

1. WHO Solidarity Trial Consortium. Pan H, Petro R, et al. Repurposed antiviral drugs for COVID-19: Interim WHO Solidarity Trial results. *MedRxiv* 2020.10.15.20209817v21[preprint]. Available at <https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1>
2. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed 15 December 2020.
3. NEMLC's COVID-19 subcommittee rapid reviews. Remdesivir 17 November 2020. Available at EMGuidance, COVID-19 Pharmacology updates <http://www.health.gov.za/index.php/national-essential-medicine-list-committee-nemlc/category/633-covid-19-rapid-reviews>